News >

FDA Approval Sought for Lenvatinib in Differentiated Thyroid Cancer

Silas Inman @silasinman
Published: Sunday, Aug 31, 2014

Dr. Martin Schlumberger

Martin Schlumberger, MD

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting. The FDA will review the application by mid-October, at which point a decision timeline under the Prescription Drug User Fee Act will be established. The fastest review under this program provides a decision within 6 months.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication